About this project / editorial, not clinical
About Prescribed PT-141
An independent editorial reading of the PT-141 (bremelanotide) research record, built around one question: what is approved, and what is not.
What this site is
Prescribed PT-141 is an independent editorial project that publishes summaries of the peer-reviewed research literature on PT-141 (bremelanotide). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The word "prescribed" in the name is editorial framing — a position this publisher occupies relative to the record. PT-141 is the rare research peptide with a genuine prescription history: an FDA-approved form (bremelanotide, NDA 210557, June 2019) for one indication, alongside an unapproved "research chemical" form. "Prescribed" signals that this digest reads the record through the lens of that approval boundary. It is not a claim that this site prescribes, dispenses, or sells anything. It does none of those things.
How we read the record
Every quantitative claim on this site maps to a numbered source on the references page — a PubMed-indexed study, a regulatory review, or the FDA prescribing information. We lead with what the published record establishes, attribute it to source, and mark the limits plainly: where the approval ends, where the evidence is preclinical, where independent re-analyses contest the effect size, and where unregulated supply sits outside any oversight.
We do not recommend a dose for any individual, and we do not tell anyone what to do. We report what was studied, in which population, at which dose, by which route, and what the studies measured. The careful line between describing a labeled dose and recommending one is a line we hold on every page.
What we don't do
We do not run a pharmacy, a telehealth service, or a clinic. We have no physical location and no clinical staff. We do not offer consultations, treatment, or prescriptions, and we do not link readers to vendors. Where the record describes the approved prescription medicine, we summarize the label; where it describes the unapproved research-chemical form, we say so. The goal is one honest, cited reading of the PT-141 record — no more, and no less.